Novartis AG (MEX:NVS N) Stock News, Headlines & Updates
Novartis AG Stock News from GuruFocus
- 1
May 25, 2024
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
PRNewswire • 6:00am
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
PRNewswire • 6:00am
Apr 25, 2024
Novartis Is Tracking Well Above the Industry
Nathan Aisenstadt • 12:19pm
Apr 24, 2024
Q1 2024 Novartis AG Earnings Call Transcript
GuruFocus Research • 11:03pm
Apr 15, 2024
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
PRNewswire • 2:00pm
Apr 06, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news